13% of general practitioners do not consider measles a dangerous disease. 12% of general practitioners consider the second dose of MMR to be useless.
33% of general practitioners do not believe that MMR vaccination should be mandatory for children under 2 years of age. (France)
The higher the level of education, age and income, the more likelihood of parents refusing the MMR, and choosing a monovalent measles vaccine. (United Kingdom)
After the MMRV vaccine, much less varicella antibodies are produced than after a separate vaccine, but more measles antibodies, as compared to MMR. .
In pre-vaccination times, 15-27% of mumps cases were asymptomatic. The number of asymptomatic cases today is unknown, as it is unclear how the vaccine modifies clinical symptoms. Orchitis (testicular inflammation) is the most common complication of mumps, but it is only possible in post-pubertal males. Orchitis is primarily unilateral. Infertility caused by mumps orchitis is quite rare, even in cases of bilateral orchitis.
Prior to introduction of the vaccine, cases of mumps were not recorded.
Monovalent mumps vaccine is virtually non-existent today, except for Japan, where MMR is still banned, mumps vaccine is not sponsored by the state, and very few people get vaccinated against it.
Here is the description of 9 cases of deafness after the MMR vaccine within four years of vaccination. The authors conclude that in 3 cases deafness was unrelated to the vaccine (but they do not provide an explanation for this conclusion), and in 6 other cases it may or may not have been related to the vaccine.
Since unilateral deafness is hard to diagnose in children, and they get vaccinated at the age of 12 months, there may have been other cases that were missed.
The authors suggest checking children’s hearing upon admission to school and comparing it to historical data, in order to understand whether the MMR vaccine affects hearing.
Another 44 cases are described here.
A few more cases of deafness after the MMR vaccine: , , , , , , , , , .
Mumps outbreak in London. 51% of the patients had been vaccinated. The effectiveness of one dose of the vaccine is 64%. The effectiveness of two doses – 88%. This effectiveness is much lower than is stated in clinical trials, since immunogenicity (i.e. the amount of antibodies) is not an accurate biological marker of the vaccine effectiveness. Moreover, the vaccines might have been improperly stored, which could have caused them to lose their effectiveness.
The authors also analyze other studies of the mumps vaccine effectiveness. In the 60s, the effectiveness was 97%, in the 70s it was 73-79%, in the 80s – 70-91% and in the 90s – 46-78% (87% for the Urabe strain).
Two weeks after the MMR vaccination of nursing students in Thailand, an outbreak of mumps occurred. The vaccine strain of the virus (Leningrad-Zagreb) was found in those infected. This strain has repeatedly caused mumps outbreaks before.
In 2013, 15 mumps outbreaks were registered in France. 72% of the cases had been vaccinated twice. The effectiveness of the vaccine was 49% for one dose and 55% for two doses.
Among those who had been vaccinated once, the risk of getting mumps increased by 7% for every year that had passed since the vaccination.
Among those who had been vaccinated twice, the risk of getting mumps increased by 10% for every year that had passed after the second dose.
Orchitis was observed in five men. One of them was unvaccinated, two had been vaccinated with one dose, and another two had been vaccinated twice.
Mumps is a mild disease, which passes on its own, but sometimes it can cause severe complications, such as orchitis, meningitis, pancreatitis or encephalitis, especially in adults. Complications from mumps are observed more often in adults and they are more severe than in children, especially among the unvaccinated.
In other countries, mumps outbreaks are also observed among the vaccinated. The reason for this is the decreasing effectiveness of the vaccine and the lack of natural boosters. Other reasons for the outbreaks could be the initial overestimation of the vaccine effectiveness, insufficient vaccination coverage, or existence of a strain that is not covered by the vaccine.
Outbreaks occurring among the vaccinated and the decreasing effectiveness, both lead to thoughts about a third dose of the vaccine. This kind of an experiment was conducted in the US during the outbreaks in 2009 and 2010. Both times the outbreak subsided a few weeks after the administration of the vaccine. However, the outbreaks always subside at some point, so it was unclear whether it had anything to do with the vaccination. Nonetheless, this and other experiments hint that a third dose of the vaccine might not be a bad idea. Moreover, during the vaccination campaigns in the US, the third dose had few side effects.
They wanted to introduce a third dose of MMR into the national immunization schedule in Netherlands, but changed their mind, since mumps rarely causes complications, and the vaccination coverage among adults is unlikely to be satisfactory.
Mumps outbreaks among the vaccinated, along with this study, led the Ministry of Health of France to recommend a third dose of MMR at times of outbreaks. Even though it is unknown whether the vaccine is effective for those already infected with the virus, it is quite possible that the vaccine will cause a decrease in the contagious period of the vaccinated patients.
The Dutch study determined that two thirds of cases during outbreaks are asymptomatic. The role of asymptomatic patients in the transmission of the disease remains unknown.
Future observations in France, and possibly other countries that would adopt the same recommendation, will help determine whether the third dose of MMR is effective during outbreaks.
In 2010, two virologists, who had previously worked for Merck, sued the company. They claimed that Merck manipulated the results of the mumps vaccine clinical trial, which allowed the company to remain the exclusive MMR manufacturer in the United States.
The lawsuit states that Merck organized a fictitious vaccine-testing program in the late 90s. The company obliged the scientists to participate in the program, promising them all bonuses if the vaccine got certified, and threatening prison if they were to report this fraud to the FDA.
The effectiveness of the mumps vaccine is determined in the following way. A blood sample is taken from children before and after vaccination. After that, a virus is added to the blood, which creates plaques as it infects the cells. Comparing the amount of these plagues in the blood before and after vaccination indicates the effectiveness of the vaccine.
Instead of testing how children’s blood neutralizes the wild virus strain, Merck was testing how it neutralizes the vaccine strain. However, this was still not enough to demonstrate the required 95% effectiveness. Thus, rabbit antibodies were added to the tested children’s blood, bringing the effectiveness level to 100%.
And that is not all of it. Since adding animal antibodies showed pre-vaccine effectiveness of 80% (instead of 10%), the fraud was evident. First, the number of added rabbit antibodies was changed, but it did not give the desired results. So they simply began to falsify the plaque counting, and counted plaques that actually were not in the blood. Falsified data was entered into an Excel file, since changing paper forms took too much time, plus this tactic did not leave any traces of falsification.
Still, the virologists did contact the FDA and the FDA sent an agent for a check. She asked questions for half an hour, received false answers, did not ask any questions the virologists themselves, did not check the lab, and wrote a one-page report, pointing to some minor issues with the process, but never mentioning neither the rabbit antibodies nor the falsified data.
As a result, Merck has received the MMR and MMRV certification, and is the sole manufacturer of these vaccines in the United States.
After the big mumps outbreaks in 2006 and 2009, the CDC, which planned on eliminating mumps by 2010, shifted the goal date to 2020.
When the court asked Merck to provide evidence of the vaccine effectiveness, they provided data from 50 years ago.
All MMR safety studies described in the section about measles are applicable to mumps as well. Here are some more:
After the mass MMR vaccination campaign in Brazil with the Japanese strain of mumps (Urabe), an outbreak of aseptic meningitis began. The risk of disease increased by 14-30 times.
The fact that Urabe strain is associated with aseptic meningitis was already known, but Brazilian authorities decided to use this strain anyway, as it is cheaper and more effective than the Jeryl Lynn strain (which is used in the US), and because they thought the risk of meningitis was quite low.
In France, vaccination with the same strain did not cause a meningitis outbreak. The authors attribute this phenomenon to the fact that the outbreaks in Brazil were observed mainly in the large cities, where people live close to hospitals. Moreover, a large number of children had been vaccinated in a very short time. These factors made it possible to identify the outbreak.
The authors worry that such side effects could lead to more people refusing vaccination. They say that people’s belief in the benefits of vaccination is no longer strong enough on its own, and that more and more people refuse vaccination, and that it would not hurt to also record side effects of the vaccination.
The following year, learning from their mistakes, the Brazilian authorities bought MMR with another strain of mumps (Leningrad-Zagreb) and vaccinated 845 thousand children with it. Another outbreak of aseptic meningitis started, and this time the risk of disease was 74 times higher. Sure, it was known that this strain also increases the risk of meningitis, but since the vaccination campaign in the Bahamas did not cause a meningitis outbreak, they decided to see how it would turn out in Brazil. Moreover, a mumps outbreak also began. One out of every 300 doses of the vaccine resulted in mumps.
The authors are wondering whether all the vaccination campaign funding should be used on vaccines, or maybe some of it should be allocated to registering side effects. They write that this issue is quite controversial in the medical literature. Supporters of prioritizing the vaccine believe that benefits of vaccination campaigns are indisputable, and that there is no need to spend money on such nonsense. Proponents of side effects monitoring believe that lack of information scares people and leads to distrust of the vaccines.
Leningrad-Zagreb strain was developed in Serbia on the basis of Leningrad-3 strain, which also caused meningitis.
In those vaccinated with MMR, the risk of hemorrhagic vasculitis was 3.4 times higher. In children, this disease usually goes away on its own, but in 1% of cases it can lead to kidney failure.
Orchitis may well occur as a result of mumps vaccine: , , , 
A 14 months old boy was given an MMR vaccine, and 4 months later he was diagnosed with a severe combined immunodeficiency. He then successfully underwent a bone marrow transplant, but developed chronic encephalitis, and died at the age of 5. A brain biopsy showed that he had the vaccine strain of the mumps virus in his brain. This was the first case of panencephalitis caused by the mumps virus.
One of the MMR components (and some other vaccines) is fetal bovine serum. Cells, in which the virus is grown, need to multiply. To do so, they need a nutrient medium with hormones, growth factors, proteins, amino acids, vitamins, etc. Fetal bovine serum is usually used as this medium. Since the serum should preferably be sterile, the blood of calves' fetuses is used instead of the cow’s blood.
A pregnant cow is killed and the uterus is removed. Then the fetus is removed from the uterus, the umbilical cord is cut and disinfected. After that the heart is punctured with a needle and the blood is pumped out. Sometimes a pump is used for this, sometimes a massage. After the blood coagulates, platelets and coagulation factors are separated from it by centrifugation. Fetal bovine serum is what remains as a result.
Apart form the necessary components, the serum can also contain viruses, bacteria, yeast, fungi, mycoplasmas, endotoxins, and possibly prions. Many components of bovine serum have not yet been identified, and the function of many of the identified ones is unknown.
150 ml of serum can be collected from a three months old fetus, 350 ml from a six month old, and 550 ml from a nine month old fetus. (Cows’ pregnancy lasts 9 months). The global market for bovine serum is 500,000 liters every year, which requires approximately 2 million pregnant cows. (Currently, the serum market is already 700,000 liters).
The authors then go on to analyze the literature on the subject of whether the fetus suffers when its heart is punctured and its blood is pumped out.
Since the fetus experiences anoxia (an acute oxygen deficiency) when separated from the placenta, perhaps it could prevent the pain signals from reaching the brain, and the fetus might not suffer. However, it turns out that, unlike adult rabbits, who die of anoxia within 1.5 minutes, prematurely born rabbits can live without oxygen for 44 minutes. This happens because fetuses and newborns compensate for oxygen deficiency with anaerobic metabolism. Moreover, fetal brain consumes much less oxygen than adult brain. Other species of animals show similar results, but calves have never been examined specifically.
Science has only recently raised the issue of whether a mammal’s fetus or newborn feels pain. Just ten years ago, infants were believed to be less sensitive to pain than adults, which is why surgeries on premature and full-term infants were performed without anesthesia. Today, it is believed that human fetus can feel pain as early as 24th week of pregnancy, and can suffer starting from week 11 after conception. Moreover, fetuses and newborns are more sensitive to pain than adults, since they have not yet developed a mechanism for suppressing physiological pain. Therefore, a fetus can even feel pain form a simple touch.
The authors conclude that normal brain activity is observed in fetus when its heart is being punctured, it feels pain and suffers when the blood is pumped out, and maybe even after the procedure, until it dies.
The authors then discuss whether it is possible to anesthetize the fetus, so that it would not feel pain. Some believe that anoxia itself plays a role of anesthetic, but that is not the case. In addition, newborn mammals have poor capacity to metabolize drugs. Also, it is undesirable to have these drugs in the serum. Electrical stunning cannot be used either, since it causes cardiac arrest. The authors believe that, perhaps, a bolt, appropriately stunned into the brain, would induce brain death.
Some manufacturers claim that they kill the fetus before harvesting blood, but that is not true, since the blood clots right after death, and to collect it the fetus must be alive.
The authors conclude that the procedure of harvesting the fetal bovine serum is inhumane.
20-50% of fetal bovine serum is infected with bovine viral diarrhea virus, as well as other viruses.
We are talking only about the viruses known to science, which constitute only a small fraction of all the existing viruses.
Fetal bovine serum contains extracellular RNA, which is impossible to separate from the serum. This RNA interacts with human cells RNA, in which vaccine viruses are grown.
The authors examined five types of live vaccines and detected bovine viral diarrhea virus RNA in MMR vaccines of two different manufacturers, as well as in two monovalent vaccines against mumps and rubella, which most likely got there from fetal bovine serum.
In infants, this virus might cause gastroenteritis, and in pregnant women, it might lead to the birth of children with microcephaly.
The fact that fetal bovine serum is infected with the bovine viral diarrhea virus was known already in 1977. It is known that this virus passes through placenta and can infect the calf fetus in the uterus. 60% of serum samples in Australia were contaminated with the virus. 8% of the vaccines against Bovine Rhinotracheitis were also contaminated.
The virus was also found in bovine kidney cells, which are used in production of measles vaccine.
A study of 30 thousand children from the UK.
Children vaccinated against diphtheria/tetanus/pertussis/polio had asthma 14 times more often and eczema – 9 times more often than unvaccinated children.
Children vaccinated against measles/mumps/rubella had asthma 3.5 times more often and eczema – 4.5 times more often.
The numbers seem to speak for themselves, right? But these figures do not suit the authors, as they want to justify vaccinations. So they do two sleights of hand.
First, they determined that unvaccinated children visit doctors less. In their opinion, this does not mean that unvaccinated children get sick less often, but rather that their chance of being diagnosed is lower than of those vaccinated! Therefore, they make a correction. It turns out not to be enough, however.
They go further and divide all children into 4 groups by the number of visits to the family doctor, and then analyze each group separately. And, oh miracle, statistical significance among those who go to the doctors often disappears! But among those who went to see doctors less then 3-6 times, the vaccinated children had asthma and eczema 10-15 times more often than the unvaccinated ones anyway.
Authors, with a clear consciousness, conclude that vaccinations do not increase the risk of asthma or eczema.
Doctors, who only read the abstract (meaning almost everyone, since only few people read these articles in full), only learn of the conclusion and, with a calm heart, go on and continue to vaccinate children.
Such sleights of hand are often found in the studies that allegedly prove the safety of vaccinations.
Children from Guinea-Bissau, who received a diphtheria/tetanus/pertussis vaccine together with the measles vaccine died twice more often that those who only received a measles vaccine.
Authors cite several more studies with the same results in Gambia, Malawi, Congo, Ghana and Senegal.
Children who received a pentavalent vaccine (diphtheria/tetanus/pertussis/Hib/hepatitis B), in addition to measles and yellow fever vaccines, died 7.7 times more often than the children who did not receive a pentavalent vaccine.
In this lecture Susan Humphries explains why the combination of live and killed vaccines leads to this effect.
In 1978, the schedule of complete measles eradication was set for the next four years. However, in 1989 it turned out that something wasn't right with the old measles vaccine, and that it was not until 1980 that they started to use a good one. But even the good vaccine was not able to eradicate measles, so in the same year they decided to introduce a second MMR dose. It also turned out that measles outbreak may very well occur in schools where 100% of children have documented vaccination record. CDC did not know how to explain this.
Today the measles vaccine is always a part of the trivalent MMR vaccine (along with rubella and mumps components), or the tetravalent MMRV vaccine (with rubella, mumps and chickenpox). Monovalent measles vaccine is not manufactured in developed countries, but it seems to still be available in Russia and some third world countries. Usually two doses are scheduled – at 12 months and at 5-6 years old.
In contrast to the inactivated vaccines, which we have examined so far, measles vaccine is an attenuated one, containing a live antigen. "Live"-attenuated vaccines are much more effective than inactivated ones, and therefore do not need aluminum adjuvants addition. One of the issues with "live" vaccines is that the attenuated viruses are able to mutate and may become virulent again, in which case vaccinated persons become infectious.
, , , , , , , , , , , , , , , , , , , , , .
In people with immune diseases, immunoglobulins are used for the measles treatment. Those are produced from the donors' blood plasma.
The authors analyzed measles titers in donors' blood, and it turned out that those born after 1990 had 7 times less antibodies than those born before 1962. The vaccination did not solve this problem, because it increased the antibodies level only two-fold, and only for a few months. The authors recommend that the FDA reduce the antibodies requirement for the immunoglobulin.
In another similar study, one year after the third MMR vaccine, the antibody count returned to its previous level.
Similar to measles, the MMR vaccine also depletes the vitamin A levels. 
Those who were not vaccinated with MMR had 33% lower incidence of allergies. Those who ate mostly organic foods had 37% lower incidence of allergies.
Allergies were also less common in those who did not use antibiotics, did not use antipyretics, had measles, ate fermented vegetables, or were breast-fed for at least 4 months.
This is a study I'd already mentioned in another chapter (Para. 10 in "Unvaccinated). Those who were vaccinated with MMR had 3.5-fold higher incidence of asthma, and 4.5-fold higher incidence of eczema.
MMR significantly reduces the function of neutrophilic leukocytes (i.e. increases susceptibility to infections). This is most likely because vaccine strains do not reproduce in lymphatic tissues like wild strains do.
The authors tested the reaction of lymphocytes to candida in vaccinated patients and found that MMR leads to reduced lymphocyte function, which lasts 1-5 weeks after vaccination. The lymphocyte function is not restored until 10-12 weeks after vaccination. Other studies have shown similar results.
Cochrane's systematic review of MMR efficiency and safety. The vaccine efficacy is 95% against measles and 88% against mumps.
The vaccine increases the risk of aseptic meningitis by a factor of 14-22 (Urabe and Leningrad-Zagreb strains), the risk of febrile convulsions by a factor of 4-5.7, the risk of thrombocytopenic purpura by a factor of 2.4-6.3.
The authors conclude that clinical and post-clinical safety studies of MMR are largely inadequate and that it is not possible to separate the role of the vaccine in preventing disease from the side effects it causes.
They recommend improving the format and reporting of clinical and post-clinical trials, and standardizing the side effects definitions. It is also required to test the longevity of MMR protective effect.
Study of side effects of 4 different MMR vaccines. 38,000 children were vaccinated. With the standard vaccine, aseptic meningitis (with a laboratory-confirmed vaccine strain of mumps in cerebrospinal fluid) was diagnosed in one in every 600 vaccinated children (aseptic meningitis in general was found in one in 400 after the standard MMR). One in every 350 vaccinated people had non-Meningitis related convulsions (40% of them had non-febrile convulsions).
One of the vaccines did not cause aseptic meningitis. It turned out that its manufacturer had done something wrong about the vaccine strains and did not report it.
In other countries, post-MMR aseptic meningitis was a less common finding (1:4000 to 1:282000) for whatever reason.
As a result of this study the Japanese Ministry of Health banned the use of MMR in 1993, and it is not used there till this day. (The study was being conducted from October 1991 to April 1993, and was published in 1996)
A healthy 12-month-old child was vaccinated with MMR, and in 8.5 months he developed encephalitis (MIBE). A brain biopsy revealed a vaccine strain of measles causing it. The child died after 1.5 months. A few more cases have been reported, but those usually occur to immunocompromised persons rather than to healthy ones.
In general, MIBE is the same panencephalitis (SSPE), a rare measles complication that occurs several years after the disease itself, but MIBE develops within a shorter timeframe and much more aggressive. Another similar case.
In another study out of nine cases of panencephalitis, three patients were vaccinated and two were not. The remaining patients' vaccination status is unknown.
The increase in the proportion of SSPE cases following measles vaccination is reported here. It is also noted that SSPE following vaccination has a shorter incubation period than SSPE following measles infection.
Despite the decrease in cases of measles-induced encephalitis after vaccination, the total number of encephalitis cases has not changed, apparently measles only has been replaced by other viruses.
In Finland the incidence of severe encephalitis cases has only increased since the introduction of MMR.
Here is a report on the measles epidemic in Vietnam in 2008 among 20-year-olds. Out of 15 cases of measles-induced encephalitis, 11 patients were vaccinated, 2 patients were not, and status of the remaining 2 was unknown.
The CDC claims that the mortality rate of measles-induced encephalitis is 15%. However, before the introduction of the vaccine, its fatality was much lower. In 1961 there were 42 reported cases of measles-induced encephalitis with no fatalities.
Case report of measles-induced encephalitis following by disability and blindness in a girl after measles vaccination in 1969.
The risk of measles-induced encephalitis increases with age. Essentially, the vaccine, which actually pushes the disease to a later date, significantly increases the risk of measles-induced encephalitis.
A 2017 British study reported that although the number of cases of measles-induced and mumps-induced encephalitis decreased by 97-98% between 1979 and 2011, the overall incidence of encephalitis increased, mainly among infants.
A study of 48 children who suffered encephalopathy after MMR. The authors conclude that there is likely to be a causal link between MMR and encephalopathy.
The incidence of emergency room visits following 12-months vaccination was 35% higher, and for girls it was 8% higher than for boys. This may be because the girls' weight is lower, or maybe because they react differently to the measles virus.
Children vaccinated with MMR were 70% more likely to have acute lymphatic leukemia.
This meta-analysis, however, did not find an increased risk of leukemia following MMR vaccination.
The risk of serious neurological disease increases 5.7-fold 6-11 days following MMR vaccination.
The risk of thrombocytopenia increases 5.5 times following MMR vaccination. More:         .
The risk of thrombocytopenia also increases following vaccination against chickenpox, TdaP and hepatitis A in older children.
The risk of febrile seizures in infants under 12 months of age who received DTP vaccination was 9.3 times higher on the day of vaccination than in children who weren't recently vaccinated.
The risk of febrile seizures in those who received MMR vaccination was 2.8 times higher during period of 8-14 days after the vaccination.
In another study, the risk of febrile seizures after MMR was 6 times higher. Similar studies: , , 
According to VAERS, 174 people have died and 742 became disabled since 2000 after being vaccinated with MMR or MMRV. During this time 4 people have died due to measles. In 2015, there was a single case of measles death in 12 years (women with chemotherapy immune deficiency). Prior to that, there were two cases in the early 2000s: an immunocompromised boy and a 75-year-old man.
On the other hand, influenza reportedly causes thousands of deaths a year in the United States. Nevertheless, almost no one is afraid of influenza while measles for some reason causes full-scale horror.
In Switzerland, one person has died of measles in the last 7 years. He was vaccinated (and he also had chemotherapy-compromised immune system). Vaccination rates in Switzerland are relatively low.
Авторы проверили 43 партии живых вакцин (MMR и OPV) разных производителей, и нашли РНК пестивирусов в 28% из них. У младенцев этот вирус возможно приводит к гастроэнтериту, а у беременных женщин - к рождению детей с микроцефалией.